OHRP Ohr Pharmaceutical Inc.

OHR INVESTOR ALERT: Faruqi & Faruqi, LLP Encourages Investors Who Suffered Losses Exceeding $50,000 Investing in OHR Pharmaceutical, Inc. to Contact the Firm

NEW YORK--(BUSINESS WIRE)--

Faruqi & Faruqi, LLP, a leading national securities law firm, is investigating potential claims against OHR Pharmaceutical, Inc. (“OHR” or the “Company”) (NASDAQ:OHRP).

On January 4, 2018, OHR issued a press release announcing negative results from its study evaluating the safety and efficacy of Squalamine, the Company’s leading therapeutic candidate for improving vision outcomes in patients suffering from ophthalmic diseases. Specifically, patients receiving the Squalamine combination therapy failed to show vision improvement over candidates receiving only a Lucentis monotherapy.

On this news, OHR’s share price declined significantly, causing harm to investors.

If you invested in OHR stock or options and would like to discuss your legal rights, click here: www.faruqilaw.com/OHR. There is no cost or obligation to you.

You can also contact us by calling Richard Gonnello toll free at 877-247-4292 or at 212-983-9330 or by sending an e-mail to [email protected].

Attorney Advertising. The law firm responsible for this advertisement is Faruqi & Faruqi, LLP (www.faruqilaw.com). Prior results do not guarantee or predict a similar outcome with respect to any future matter. We welcome the opportunity to discuss your particular case. All communications will be treated in a confidential manner.

EN
22/02/2018

Underlying

OHRPOhr Pharmaceutical Inc.

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on Ohr Pharmaceutical Inc.

 PRESS RELEASE
Free
OHRP Ohr Pharmaceuti...

Ohr Pharmaceutical, Inc. Announces Stockholder Approval of Merger Agre...

Ohr Pharmaceutical, Inc. Announces Stockholder Approval of Merger Agreement with NeuBase Therapeutics, Inc. NEW YORK, July 10, 2019 (GLOBE NEWSWIRE) -- Ohr Pharmaceutical, Inc. (“Ohr”) (Nasdaq: OHRP) today announced that all proposals related to its proposed merger with NeuBase Therapeutics, Inc. (“NeuBase”) were approved by Ohr’s stockholders at a special meeting held on July 10, 2019. As previously announced on January 3, 2019, the proposed merger will create a public company under which the stockholders of NeuBase will become majority holders of the combined company. Upon closing of t...

July 10, 2019 1 EN
 PRESS RELEASE
Free
OHRP Ohr Pharmaceuti...

Ohr Pharmaceutical Urges Stockholders to Vote “FOR” Merger with Ne...

Ohr Pharmaceutical Urges Stockholders to Vote “FOR” Merger with NeuBase Therapeutics at Special Meeting on July 10, 2019 -- Of the Votes Received to Date, More than 99% Are Voting in Favor of the Merger Proposal-- More Votes Are Needed to Reach 50% of the Outstanding Shares to Go Forward with the Special Meeting-- Every Vote Is Important to Avoid Delay in Completion of the Merger NEW YORK, July 03, 2019 (GLOBE NEWSWIRE) -- Ohr Pharmaceutical, Inc. (Nasdaq: OHRP) (the “Company” or “Ohr”) reiterated the unanimous recommendation of its Board of Directors that stockholders vote “FOR” all of ...

July 3, 2019 1 EN
 PRESS RELEASE
Free
OHRP Ohr Pharmaceuti...

Ohr Pharmaceutical Reports Financial Results for the Fiscal Second Qua...

Ohr Pharmaceutical Reports Financial Results for the Fiscal Second Quarter of 2019 Preliminary proxy materials for the proposed merger with NeuBase Therapeutics filed with the SEC; Stockholder vote is expected to occur in the middle of calendar 2019 NEW YORK, May 15, 2019 (GLOBE NEWSWIRE) -- Ohr Pharmaceutical, Inc. (Nasdaq: OHRP) (the “Company” or “Ohr”) today reported financial results for the three and six month periods ended March 31, 2019. "We continue to be excited by the opportunity to merge with NeuBase Therapeutics, a privately-held biotechnology company developing next-genera...

May 15, 2019 1 EN
 PRESS RELEASE
Free
OHRP Ohr Pharmaceuti...

Ohr Pharmaceutical Regains Compliance with NASDAQ Listing Requirements

Ohr Pharmaceutical Regains Compliance with NASDAQ Listing Requirements NEW YORK, Feb. 21, 2019 (GLOBE NEWSWIRE) -- Ohr Pharmaceutical, Inc. (Nasdaq: OHRP) today announced that it received notice from The Nasdaq Stock Market LLC indicating that the Company has regained compliance with the minimum bid price requirement under NASDAQ Listing Rule 5550(a)(2) (the "Bid Price Rule") for continued listing on The NASDAQ Capital Market. Accordingly, the Company has regained compliance with the Bid Price Rule and NASDAQ considers the matter closed. Ohr Pharmaceutical Contact: Investor Relations    ...

February 21, 2019 1 EN
 PRESS RELEASE
Free
OHRP Ohr Pharmaceuti...

Ohr Pharmaceutical Reports Financial Results for the Fiscal First Quar...

Ohr Pharmaceutical Reports Financial Results for the Fiscal First Quarter of 2019 Stockholder vote on the proposed merger with NeuBase Therapeutics anticipated in the second calendar quarter of 2019 NEW YORK, Feb. 14, 2019 (GLOBE NEWSWIRE) -- Ohr Pharmaceutical, Inc. (Nasdaq: OHRP) (the “Company” or “Ohr”) today reported financial results for the three months ended December 31, 2018. “Since we announced the signing of a definitive agreement to merge with NeuBase Therapeutics, Inc., a privately-held biotechnology company, we have been working diligently to bring the proposed merger with...

February 14, 2019 1 EN

ResearchPool Subscriptions

Get the most out of your insights

Get in touch